With coronavirus vaccines now available, what are the timeline and prospects for "herd immunity" and return to a new normal? Marc Lipsitch, DPhil, of Harvard T.H. Chan School of Public Health returns to JAMA's Q&A; series with Paul D. Biddinger, MD, director of Massachusetts General Hospital's Center for Disaster Medicine, to discuss. Recorded December 17, 2020. Related Article:  The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials

COVID-19 Vaccines and Herd Immunity

Conversations with experts and frontline clinicians about the COVID-19 pandemic, hosted by editors from the JAMA Network.

Medicine

Science & Medicine

Science

Health & Fitness

Interview with Churl-Su Kwon, MD, MPH, author of Association of New-Onset Seizures With SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Hosted by Cynthia E. Armand, MD.  Related Content:  Association of New-Onset Seizures With SARS-CoV-2 Vaccines 

Association of New-Onset Seizures With SARS-CoV-2 Vaccines

Benjamin D. Sommers, MD, PhD, of Harvard University, speaks with JAMA Health Forum Editor John Ayanian, MD, MPP, and Deputy Editor Melinda Buntin, PhD, about differences in Medicaid enrollment as measured in surveys and administrative data. These differences have implications for estimating coverage now that the federal policy of continuous Medicaid eligibility during the COVID-19 pandemic has ended.  Related Content:  Survey-Reported Coverage in 2019-2022 and Implications for Unwinding Medicaid Continuous Eligibility 

Measuring Medicaid Enrollment More Accurately to Guide Post–COVID-19 Pandemic Policy

Rural Maternity Care Is in Crisis—Here’s What Could Help; Type and Severity of Immunodeficiency Affect Speed of SARS-CoV-2 Clearance, Study Finds  Related Content:  More Than Half of US Rural Hospitals No Longer Offer Birthing Services—Here’s Why When It Comes to SARS-CoV-2 Clearance, People Who Are Immunocompromised Are Not All Alike 

February 2024 Medical News Summary

Bivalent mRNA COVID-19 vaccines were recommended for children and adolescents aged 5 to 17 years in the US, but were they effective? JAMA Associate Editor Tracy A. Lieu, MD, MPH, spoke with author Leora R. Feldstein, PhD, US Centers for Disease Control and Prevention, about the effectiveness of bivalent COVID-19 vaccines in children and adolescents.  Related Content:  Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years 

Evaluating the Effectiveness of Bivalent COVID-19 Vaccines in Children and Adolescents

The COVID-19 pandemic has caused major disruptions in ambulatory care. In this interview with JAMA Health Forum Editor John Ayanian, MD, MPP, and Deputy Editor Melinda Buntin, PhD, Rishi K. Wadhera, MD, MPP, MPhil, of Harvard Medical School discusses how access to care and preventive services changed for different racial and ethnic groups in the US from 2019 to 2022.  Related Content:  Changes in Health Care Access and Preventive Health Screenings by Race and Ethnicity 

COVID-19 Vaccines and Herd Immunity

Download our free app to listen on your phone